Condition
Acute Myeloid Leukemia, Adult clinical trials and research
As of November 12, 2026, Find a Trial lists 9 Acute Myeloid Leukemia, Adult clinical trials that are recruiting, at sites in 19 countries (most in Italy (2), China (2), Germany (2)). By phase: Phase 1/2 (3), Phase 3 (2), Phase 2 (2), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 9Clinical trials
- 19Countries
Newest Acute Myeloid Leukemia, Adult clinical trials
All recruiting trials (9)
-
Venetoclax and Azacitidine with or without Quizartinib in older/unfit adults with AML
This trial tests whether adding Quizartinib to Venetoclax and Azacitidine helps older or unfit adults with AML live longer compared with the standard Venetoclax and Azacitidine therapy.
-
Combining revumenib with azacitidine and venetoclax for treating specific types of acute myeloid leukemia
This study is testing a new combination of medications to see if it can help people with specific types of acute myeloid leukemia who can't have intensive chemotherapy.
-
Comparing different drug combinations for newly diagnosed acute myeloid leukemia
This study is testing different combinations of drugs to see which one works best for people with newly diagnosed acute myeloid leukemia who can't handle strong chemotherapy.
-
Real-world outcomes for adults with AML treated with new drugs (BoxTrial)
This project will follow adults with AML treated in routine care across Italy to see how new approved drugs and combinations perform over at least two years.
-
Multi-peptide vaccine with XS15 for adults with acute myeloid leukemia in remission
A small early study will test a multi-peptide vaccine with XS15 to see if it’s safe and can trigger immune responses in AML patients who are in complete remission after first-line therapy.
-
Hydroxyurea plus valproic acid or 6‑mercaptopurine plus valproic acid for unfit adults with AML or high‑risk MDS
This study will try two low‑toxicity oral drug combinations—hydroxyurea plus valproic acid, or 6‑mercaptopurine plus valproic acid—in adults with acute myeloid leukemia or high‑risk myelodysplastic syndrome who are not fit for standard chemotherapy.
-
Evaluating ABD-3001 for patients with difficult-to-treat blood cancers
This study is testing a new treatment called ABD-3001 to see if it can help adults with hard-to-treat blood cancers like Acute Myeloid Leukemia and high-risk Myelodysplastic Syndromes feel better and stay safe during the process.
-
Combining Clifutinib Besylate with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
This study is testing if adding Clifutinib Besylate to standard chemotherapy helps adults who are newly diagnosed with Acute Myeloid Leukemia feel better and respond to treatment.
-
Treatment for patients with difficult-to-treat acute myeloid leukemia
This study is testing a new combination of chemotherapy drugs to see if it can help adults with tough-to-treat acute myeloid leukemia that hasn't responded to previous treatments.
Related topics
Quick answers
How many Acute Myeloid Leukemia, Adult clinical trials are recruiting right now?
9, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 19 countries. The most sites are in Italy (2 trials), China (2 trials), Germany (2 trials), Norway (2 trials), Spain (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 3, Phase 3: 2, Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.